Fig. 1: The principle of the functional precision oncology (fPO) pipeline.

Patient-derived cancer cells (PDCs) established from HGSOC, LGSOC and MUCOC tumour or ascites samples were subjected to molecular characterisation and functional drug testing platform covering up to 526 drugs to identify patient-selective drug vulnerabilities that can be translated back to the clinics in real-time. Figure was created with BioRender.com.